These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 19791315)
61. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly. Vladeck DC Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967 [No Abstract] [Full Text] [Related]
62. The reach of free speech: recent rulings make it tough to nail down the boundaries of protected speech and other thorny state-federal issues. Savage DG State Legis; 2011; 37(9):26-9. PubMed ID: 22069842 [No Abstract] [Full Text] [Related]
63. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public? Levy E Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481 [No Abstract] [Full Text] [Related]
65. The Medical Device Safety Act of 2009. Curfman GD; Morrissey S; Drazen JM N Engl J Med; 2009 Apr; 360(15):1550-1. PubMed ID: 19297562 [No Abstract] [Full Text] [Related]
66. The Canadian perspective: trends in drug and medical device class actions in Canada. Vernon W Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040 [No Abstract] [Full Text] [Related]
67. Drug counterfeiting burden remains a guess, experts say. Traynor K Am J Health Syst Pharm; 2009 Jul; 66(14):1246-8. PubMed ID: 19574593 [No Abstract] [Full Text] [Related]
68. Restrictions on the use of prescribing data for drug promotion. Mello MM; Messing NA N Engl J Med; 2011 Sep; 365(13):1248-54. PubMed ID: 21812664 [No Abstract] [Full Text] [Related]
70. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions. Chodock R; Yolkut D; Connolly DR Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814 [TBL] [Abstract][Full Text] [Related]
71. Accidental intra-arterial injection: a case report, new treatment modalities, and a review of the literature. Keene JR; Buckley KM; Small S; Geldzahler G J Oral Maxillofac Surg; 2006 Jun; 64(6):965-8. PubMed ID: 16713815 [No Abstract] [Full Text] [Related]
72. Neuroleptic malignant syndrome with promethazine. Mendhekar DN; Andrade C Aust N Z J Psychiatry; 2005; 39(1-2):113-4. PubMed ID: 15660719 [No Abstract] [Full Text] [Related]
73. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
74. Why doctors should worry about preemption. Curfman GD; Morrissey S; Drazen JM N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269 [No Abstract] [Full Text] [Related]
75. Repositioning Generics: The Comparative Value of Liability in FDA's Proposed Rule on Labeling. Falcone N Am J Law Med; 2015; 41(2-3):483-504. PubMed ID: 26591830 [No Abstract] [Full Text] [Related]
76. Comment: Promethazine adverse events after implementation of a medication shortage interchange. Habib AS; Breen TW; Gan TJ Ann Pharmacother; 2005; 39(7-8):1370; author reply 1370-1. PubMed ID: 15956221 [No Abstract] [Full Text] [Related]
77. Revisiting Factor VIII cases: is it time for an agency adjudication system? Su YC Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390 [No Abstract] [Full Text] [Related]
78. Merck KGaA v. Integra Lifesciences I, Ltd: implications of the supreme court's decision for the people who matter most...the consumer. Jaquette I Am J Law Med; 2007; 33(1):97-117. PubMed ID: 17547356 [No Abstract] [Full Text] [Related]
79. Prescriptions, privacy, and the First Amendment. Curfman GD; Morrissey S; Drazen JM N Engl J Med; 2011 May; 364(21):2053-5. PubMed ID: 21524208 [No Abstract] [Full Text] [Related]
80. [Responsibility for patient education in drug therapy from the viewpoint of the pharmaceutical industry]. Sander A Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1061-3. PubMed ID: 7716983 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]